Digital Breast Tomosynthesis Doses Comparable to Mammography
Radiation doses from digital breast tomosynthesis is comparable to and could be lower than conventional two-view full-field digital mammography.
Radiation doses from digital breast tomosynthesis is comparable to and could be lower than conventional two-view full-field digital mammography, show findings of a study published in the April issue of Radiology.
Researchers from Emory University School of Medicine in Atlanta, Ga., compared dose levels of digital breast tomosynthesis (DBT) and full-field digital mammography (FFDM) by using compressible water-oil mixture breast phantoms of varying sizes to determine how much radiation dose would be used for varying sizes and glandular compositions of breasts.
When comparing doses with the “average” breast (compressed thickness of 5 cm, 50 percent glandular fraction), a DBT acquisition resulted in 1.30 mGy, only an 8 percent higher mean glandular dose than the FFDM acquisition of 1.20 mGy. For a thicker breast sample (6.0 cm and 14.3 percent glandular fraction), a DBT acquisition was 2.12 mGy, which was 83 percent higher than an FFDM acquisition of 1.16 mGy.
RELATED: Practices Adjust Workflow IT for Tomosynthesis Adoption
Although the thicker breast had a higher dose, the researchers pointed out that this was still lower than the 3 mGy limit for a single-view conventional study, which is set by the Mammography Quality Standards Act.
Potentially, screening DBT could reduce the recall rate, reducing the number of repeat scans, which reduces women’s overall radiation dose rate.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
